For decades, researchers believed they understood the source of the severe inflammation that accompanies a rare genetic disorder. That long-held view is now under scrutiny. Scientists at the Garvan Institute of Medical Research have gathered evidence that challenges three decades of established thinking and may open the way to a new treatment.
The disorder, called mevalonate kinase deficiency (MKD), can trigger inflammatory episodes that are sometimes severe and even life-threatening. In a new study published in Immunity, the researchers identify a previously underappreciated problem involving natural killer (NK) cells, the immune cells that normally help the body eliminate infected cells.
In people with MKD, these cells malfunction, unleashing an excessive inflammatory response whenever an infection occurs. The finding also points to a possible treatment using existing drugs known as JAK inhibitors, a strategy that could prove especially valuable for patients who do not respond to current therapies.
“This study has revealed a new target for this inflammatory disorder and sets the scene for future clinical studies to explore the use of JAK inhibitors or other drugs to neutralize interferon gamma in patients with MKD,” says Professor Mike Rogers, Lab Head at Garvan and senior author of the study. “This could lead to a targeted treatment that hasn’t been tried before.”
Why a Rare Immune Disease Triggers Dangerous Inflammation
MKD is a lifelong condition known to affect hundreds of children and adults worldwide, though researchers suspect that many cases remain undiagnosed. Patients endure recurring attacks of high fever, skin rashes, joint pain, and inflammation of the abdomen. The most severe episodes can lead to potentially fatal complications.
For roughly three decades, research into the disease has focused largely on macrophages, the immune cells that help coordinate the body’s inflammatory defenses. Current treatments are designed to block an inflammatory signal released by these cells. Yet about half of patients respond poorly to them, leaving a significant unmet need for better options.
To understand what the prevailing explanation might be missing, the Garvan team analyzed blood samples from people with MKD and studied preclinical models of the disorder.
Their experiments uncovered a substantial defect in natural killer cells, which are central to the body’s early defense against viral infections. In MKD, these cells fail to mature properly and cannot carry out one of their key functions: destroying infected cells before an infection spreads.
The consequences extend well beyond a weakened ability to fight infection. When natural killer cells cannot destroy their targets, they release large quantities of inflammatory signaling molecules, activating other parts of the immune system and potentially setting off widespread inflammation.
“We found that these immune cells are essentially misfiring,” explains Professor Rogers. “NK cells are loaded with toxic ammunition, stored in granules that are released to kill infected cells. However, in MKD these toxic granules can’t be released from NK cells and remain trapped inside. When an NK cell fails to kill its target, it compensates by shouting for help, pumping out large amounts of interferon gamma – a powerful inflammatory signal. This activates other immune cells and causes the dangerous fever and widespread inflammation seen in patients.”
Finding Rewrites Three Decades of Immune Disease Research
The results indicate that the dysfunction of natural killer cells, rather than macrophage activity alone, is a central driver of MKD.
Dr. Marcia Munoz, Group Leader in the Rogers Lab and lead researcher on the study, says the findings mark a significant shift in how scientists understand the disease.
“This really turns on its head 30 years of dogma about what was thought to be the underlying mechanism of disease. In MKD, the primary problem is in NK cells and not in macrophages, as previously believed,” she says.
To explore how this cellular defect contributes to the disorder, the Garvan researchers worked with Professor Mariapia Degli-Esposti and scientists at Monash University.
Using preclinical models, the team established a link between malfunctioning natural killer cells and the severe symptoms of MKD. Their experiments demonstrated that when the immune system fails to clear a viral infection, the resulting inflammatory response can inflict extensive organ damage.
These results help explain why a disorder rooted in defective immune defenses can also produce episodes of extreme inflammation.
Existing Drug Holds Promise as a New Treatment
The discovery has already informed an experimental treatment approach for a severely affected infant.
Collaborating with clinicians at the Royal Children’s Hospital in Melbourne, the researchers examined whether baricitinib could dampen the excessive inflammatory signaling associated with MKD.
Baricitinib belongs to a class of drugs called JAK inhibitors, which interfere with the signaling pathways the immune system uses, including those involved in responses to interferon gamma. The medication is already approved to treat other immune-related conditions, such as rheumatoid arthritis and eczema.
Doctors added baricitinib to the infant’s existing treatment regimen and subsequently observed an improvement in the child’s condition. Inflammatory flare-ups became less frequent, and severe inflammation affecting the gastrointestinal tract began to heal.
Although outcomes in a single patient cannot establish whether the treatment will work more broadly, the improvement offers encouraging early evidence for a strategy that targets a different stage of the inflammatory process.
The researchers believe their findings lay the groundwork for future clinical studies of JAK inhibitors and other drugs that block interferon gamma activity in patients with MKD, particularly those who have not responded to standard treatments.
Findings May Illuminate Other Genetic Diseases
The potential implications reach beyond MKD itself.
Researchers have coined the term ‘prenylopathies’ to describe a family of genetic disorders that involve the same metabolic pathway disrupted in MKD. Early findings suggest these related conditions may share a common underlying problem: natural killer cells that malfunction and instead generate excessive inflammatory signals.
If further studies confirm this connection, scientists may be able to pinpoint shared disease mechanisms and develop more targeted approaches to diagnosis and treatment across several disorders.
“Confirming this link could help end the diagnostic odyssey many patients endure for years or even decades before receiving effective treatment,” says Professor Rogers.
Professor Mike Rogers is a Conjoint Professor at St Vincent’s Clinical School, Faculty of Medicine and Health, UNSW Sydney. Dr. Marcia Munoz is a Conjoint Senior Lecturer at St Vincent’s Clinical School, Faculty of Medicine and Health, UNSW Sydney.
Also Read
- Science Review Explores Cognitive Effects of GLP-1 Drugs Amid Mixed Alzheimer’s Trial Results
- Massive Abdominal Cyst Misdiagnosed as Cancer Turns Out to Be Lymphatic Filariasis
- NHS England Faces Scrutiny After 3,000 Patient Record Snooping Cases
- A Two-Week Nosebleed Defied Treatment Until Doctors Uncovered a Live Leech Inside a Man’s Nose

